⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430949 | 0.79 | — | — | |
| SCHEMBL28583300 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL419805 | 0.76 | MEN1 (0.32) | — | |
| SCHEMBL1289421 | 0.76 | MEN1 (0.32) | — | |
| SCHEMBL1784891 | 0.73 | — | — | |
| SCHEMBL5254948 | 0.72 | — | — | |
| SCHEMBL7291462 | 0.70 | CA2 (0.38) | — | |
| SCHEMBL785513 | 0.70 | CA2 (0.38) | — | |
| SCHEMBL2385202 | 0.70 | — | — | |
| SCHEMBL7737959 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195260-A1 | LPXC INHIBITOR AND METHODS OF MAKING | FORGE THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | claimed |
| US-20240182487-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240174679-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-4251149-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023101895-A1 | FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-3523311-B1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3177618-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170101398-A1 | PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES | Grünenthal GmbH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101397-A1 | PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES | Grünenthal GmbH (DE) | 2017-04-13 | — | — | US | disclosed |
| WO-2017059966-A1 | PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES | Grünenthal GmbH (DE) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017059965-A1 | PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES | Grünenthal GmbH (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160046618-A1 | Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use | AMGEN INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2016022724-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-02-11 | — | — | WO | disclosed |